Aquestive Therapeutics (NASDAQ:AQST) Receives "Buy" Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST - Free Report) in a research note issued to investors on Friday,Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock.

Other equities research analysts also recently issued research reports about the company. Leerink Partners lifted their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Cantor Fitzgerald assumed coverage on shares of Aquestive Therapeutics in a report on Tuesday. They issued an "overweight" rating and a $17.00 price objective for the company. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $9.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Aquestive Therapeutics has an average rating of "Buy" and an average price target of $11.00.

Aquestive Therapeutics Price Performance

Aquestive Therapeutics stock traded up $0.01 during trading hours on Friday, hitting $3.65. The company had a trading volume of 1,344,092 shares, compared to its average volume of 1,739,676. The firm has a 50-day moving average of $4.74 and a 200 day moving average of $4.06. The firm has a market cap of $332.80 million, a PE ratio of -8.11 and a beta of 2.62. Aquestive Therapeutics has a one year low of $1.84 and a one year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). The firm had revenue of $13.54 million during the quarter, compared to the consensus estimate of $12.69 million. During the same quarter in the prior year, the business posted ($0.03) EPS. As a group, research analysts expect that Aquestive Therapeutics will post -0.47 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. bought a new position in shares of Aquestive Therapeutics in the 2nd quarter valued at $27,000. nVerses Capital LLC bought a new stake in shares of Aquestive Therapeutics during the third quarter worth about $28,000. The Manufacturers Life Insurance Company bought a new stake in shares of Aquestive Therapeutics during the second quarter worth about $76,000. Financial Advocates Investment Management increased its stake in shares of Aquestive Therapeutics by 70.0% in the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company's stock valued at $88,000 after buying an additional 14,000 shares during the period. Finally, Harvey Capital Management Inc. bought a new position in Aquestive Therapeutics in the 3rd quarter valued at approximately $88,000. Institutional investors own 32.45% of the company's stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.